Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study
Thomas J. Povsic, Roxana Mehran(Mount Sinai Hospital), Jan H. Cornel(Brigham and Women's Hospital), Christopher E. Buller(Teleflex (United States)), Gilles Montalescot(Maastricht University Medical Centre), John P. Vavalle(Clinical Research Institute), Steven L. Zelenkofske(Novartis (Switzerland)), Peter Fail, Ian J. Sarembock(Christ Hospital), John H. Alexander(Ohio State University Hospital), Jarosław D. Kasprzak(Medical University of Lodz), Richard C. Becker(Clinical Research Institute), Laura H. Aberle(Clinical Research Institute), Mauricio G. Cohen(Santa Ana College)
Cited by 29
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k